piracetam has been researched along with Hemorrhage, Subarachnoid in 14 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current guidelines recommend against the use of phenytoin following aneurysmal subarachnoid hemorrhage (aSAH) but consider other anticonvulsants, such as levetiracetam, acceptable." | 7.80 | Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage. ( Fletcher, JJ; Karamchandani, RR; Pandey, AS; Rajajee, V, 2014) |
| "To determine the utility and tolerability of levetiracetam (LEV) compared to phenytoin (PHT) in preventing clinical seizures in patients with subarachnoid hemorrhage (SAH)." | 7.75 | Utility of levetiracetam in patients with subarachnoid hemorrhage. ( Husain, AM; Shah, D, 2009) |
| " Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded." | 5.37 | Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. ( Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011) |
| "Treatment with levetiracetam also improved functional outcomes and reduced vasospasm following SAH." | 5.33 | Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. ( Gao, J; Laskowitz, DT; Lassiter, TF; Lynch, JR; McDonagh, DL; Sheng, H; Wang, H; Warner, DS, 2006) |
| "In this prospective, single-center, randomized, single-blinded comparative trial of LEV versus PHT (2:1 ratio) in patients with severe traumatic brain injury (sTBI) or subarachnoid hemorrhage (NCT00618436) patients received IV load with either LEV or fosphenytoin followed by standard IV doses of LEV or PHT." | 5.14 | Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. ( Lindsell, CJ; Sangha, KS; Shutter, LA; Szaflarski, JP, 2010) |
| "Patients may experience a reduced incidence of clinical and electroencephalographic seizures with levetiracetam dosing >1000-mg TDD." | 4.31 | Levetiracetam dosing for seizure prophylaxis in neurocritical care patients. ( Ansari, S; Davis, GE; Findlay, MC; Hawryluk, GWJ; Hedges, A; Menacho, ST; Wolfe, BM, 2023) |
| "Current guidelines recommend against the use of phenytoin following aneurysmal subarachnoid hemorrhage (aSAH) but consider other anticonvulsants, such as levetiracetam, acceptable." | 3.80 | Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage. ( Fletcher, JJ; Karamchandani, RR; Pandey, AS; Rajajee, V, 2014) |
| "To determine the utility and tolerability of levetiracetam (LEV) compared to phenytoin (PHT) in preventing clinical seizures in patients with subarachnoid hemorrhage (SAH)." | 3.75 | Utility of levetiracetam in patients with subarachnoid hemorrhage. ( Husain, AM; Shah, D, 2009) |
| " Prospective, open-label, steady-state pharmacokinetic study." | 2.76 | Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ( Fleck, JD; Jacobi, J; Juenke, JM; Kays, MB; Spencer, DD, 2011) |
| " The overall conclusions from 2 recent studies in aneurysmal subarachnoid hemorrhage are that 1) many patients receive AEDs but should not; 2) long-term use is associated with worse outcome; and 3) short-term use is safer." | 2.44 | Antiepileptic drugs in aneurysmal subarachnoid hemorrhage. ( Wijdicks, EF; Zubkov, AY, 2008) |
| "fosphenytoin (fos-PHT) seizure prevention trial (NCT00618436)." | 1.38 | Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention. ( Lindsell, CJ; Shutter, LA; Steinbaugh, LA; Szaflarski, JP, 2012) |
| " Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded." | 1.37 | Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. ( Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011) |
| "Treatment with levetiracetam also improved functional outcomes and reduced vasospasm following SAH." | 1.33 | Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. ( Gao, J; Laskowitz, DT; Lassiter, TF; Lynch, JR; McDonagh, DL; Sheng, H; Wang, H; Warner, DS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Hedges, A | 1 |
| Findlay, MC | 1 |
| Davis, GE | 1 |
| Wolfe, BM | 1 |
| Hawryluk, GWJ | 1 |
| Menacho, ST | 1 |
| Ansari, S | 1 |
| Karamchandani, RR | 1 |
| Fletcher, JJ | 1 |
| Pandey, AS | 1 |
| Rajajee, V | 1 |
| Bugeme, M | 1 |
| Mukuku, O | 1 |
| García Estévez, DA | 1 |
| García-Dorrego, RM | 1 |
| Nieto-Baltar, B | 1 |
| Marey-Garrido, M | 1 |
| Hierro-Torner, T | 1 |
| Zubkov, AY | 1 |
| Wijdicks, EF | 1 |
| Shah, D | 1 |
| Husain, AM | 1 |
| Szaflarski, JP | 2 |
| Sangha, KS | 1 |
| Lindsell, CJ | 2 |
| Shutter, LA | 2 |
| Usami, K | 1 |
| Saito, N | 1 |
| Murphy-Human, T | 1 |
| Welch, E | 1 |
| Zipfel, G | 1 |
| Diringer, MN | 1 |
| Dhar, R | 1 |
| Mink, S | 1 |
| Muroi, C | 1 |
| Seule, M | 1 |
| Bjeljac, M | 1 |
| Keller, E | 1 |
| Spencer, DD | 1 |
| Jacobi, J | 1 |
| Juenke, JM | 1 |
| Fleck, JD | 1 |
| Kays, MB | 1 |
| Steinbaugh, LA | 1 |
| Drust, A | 1 |
| Luchtmann, M | 1 |
| Firsching, R | 1 |
| Tröger, U | 1 |
| Martens-Lobenhoffer, J | 1 |
| Bode-Böger, SM | 1 |
| Wang, H | 1 |
| Gao, J | 1 |
| Lassiter, TF | 1 |
| McDonagh, DL | 1 |
| Sheng, H | 1 |
| Warner, DS | 1 |
| Lynch, JR | 1 |
| Laskowitz, DT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage[NCT01935908] | Phase 4 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to no funding) | ||
| A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide[NCT01110187] | 11 participants (Actual) | Interventional | 2010-05-31 | Terminated (stopped due to Lack of enrollement) | |||
| A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury[NCT04836481] | 20 participants (Anticipated) | Observational | 2021-01-01 | Recruiting | |||
| Levetiracetam Treatment of Neonatal Seizures: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Oral Levetiracetam as First Line Treatment for Neonatal Seizures in China[NCT02550028] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2015-09-01 | Terminated (stopped due to The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.) | ||
| Assessment of Seizure Prophylaxis Protocols Using Intravenous Levetiracetam in a Neuroscience Intensive Care Unit[NCT00618436] | Phase 4 | 52 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome measure is the incidence of clinical adverse events. These will be followed by daily clinical observations during the hospital stay. Subjects will be evaluated for e.g., seizures, fever, neurological changes, cardiovascular, hematologic and dermatologic abnormalities, liver failure, renal failure, and death; EKGs will be requested as per ICU routines through day 7. (NCT01110187)
Timeframe: baseline to 7 days
| Intervention | number of events experienced (Number) |
|---|---|
| IV LCM | 12 |
| IV fPHT | 21 |
Number of seizures in the first 72 hours based on EEG recording (NCT01110187)
Timeframe: baseline to 72 hours
| Intervention | number of participants with seizures (Number) |
|---|---|
| IV LCM | 0 |
| IV fPHT | 0 |
This was the number of patients in each group who demonstrated seizure activity during the course of the study (NCT00618436)
Timeframe: Duration of study, up to 6 months after the injury
| Intervention | Participants (Number) |
|---|---|
| Levetiracetam | 5 |
| Phenytoin | 3 |
The Disability rating scale (DRS) is frequently used in the rehabilitation literature as a measure of disability. It is a reliable, easily performed test that assesses 8 items (eye opening, verbalization, motor response, feeding, toileting, grooming, level of functioning, employability), and assigns each a numerical score ranging from 0 - 5 based on the category. The domains these 8 items are felt to assess include: alertness, cognition for self-care, dependence, and psychosocial adaptability. The scoring range is from 0-30, with increasing disability levels assigned to higher numerical values. The total DRS is then dichotomized into favorable (disability = none, mild, partial or moderate disability) and unfavorable (disability = moderately severe, severe, extremely severe, vegetative state, extreme vegetative state, death) outcomes. A DRS score of 0-6 was favorable, with any score greater than 6 categorized as unfavorable. (NCT00618436)
Timeframe: Discharge; 3 and 6 months following injury
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| At Discharge | At 3 months | At 6 months | |
| Levetiracetam | 24 | 15 | 17 |
| Phenytoin | 23 | 13 | 9 |
This is an 8 point validated scale that measures disability after brain injury. It is assessed through an in person exam or by phone interview at hospital discharge, 3 months and 6 months after injury. The categories are: 1 = dead; 2 = vegetative state; 3 = severe disability, low level; 4 = severe disability, high level; 5 = moderate disability, low level; 6 = moderate disability, high level; 7 = good recovery - low level; 8 = good recovery - high level. Specific questions and activities are assessed to determine into which category the patient falls. (NCT00618436)
Timeframe: at discharge; 3 and 6 months following injury
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| At Discharge | At 3 months | At 6 months | |
| Levetiracetam | 2 | 3 | 3 |
| Phenytoin | 2 | 3 | 3 |
2 reviews available for piracetam and Hemorrhage, Subarachnoid
| Article | Year |
|---|---|
[Neuropsychiatric manifestations revealing cerebral subarachnoid hemorrhage caused by electrification accident about a case and review of literature].
Topics: Accidents, Home; Brain Edema; Child; Child Behavior Disorders; Confusion; Dexamethasone; Electric In | 2014 |
Antiepileptic drugs in aneurysmal subarachnoid hemorrhage.
Topics: Animals; Anticonvulsants; Electroencephalography; Head Injuries, Closed; Humans; Levetiracetam; Neur | 2008 |
2 trials available for piracetam and Hemorrhage, Subarachnoid
| Article | Year |
|---|---|
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients.
Topics: Anticonvulsants; Brain Injuries; Critical Care; Female; Hematoma, Subdural; Humans; Infusions, Intra | 2011 |
10 other studies available for piracetam and Hemorrhage, Subarachnoid
| Article | Year |
|---|---|
Levetiracetam dosing for seizure prophylaxis in neurocritical care patients.
Topics: Adult; Anticonvulsants; Brain Injuries, Traumatic; Female; Humans; Levetiracetam; Male; Middle Aged; | 2023 |
Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Brain Ischemia; Female; Follow-Up Stud | 2014 |
Spontaneous convexity subarachnoid haemorrhage: Clinical series of 3 patients with associated cerebral amyloid angiopathy.
Topics: Aged; Anticonvulsants; Brain; Cerebral Amyloid Angiopathy; Dexamethasone; Female; Glucocorticoids; H | 2017 |
Utility of levetiracetam in patients with subarachnoid hemorrhage.
Topics: Adult; Aged; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Levetiracetam; Male; Midd | 2009 |
Prophylactic anticonvulsants after subarachnoid hemorrhage.
Topics: Anticonvulsants; Epilepsy; Humans; Incidence; Levetiracetam; Phenytoin; Piracetam; Subarachnoid Hemo | 2011 |
Comparison of short-duration levetiracetam with extended-course phenytoin for seizure prophylaxis after subarachnoid hemorrhage.
Topics: Adult; Aged; Anticonvulsants; Databases, Factual; Delayed-Action Preparations; Disease-Free Survival | 2011 |
Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
Topics: Administration, Oral; Aged; Aneurysm, Ruptured; Anti-Bacterial Agents; Anticonvulsants; Biological A | 2011 |
Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Disability Evaluation; | 2012 |
Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Disability Evaluation; | 2012 |
Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Disability Evaluation; | 2012 |
Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Disability Evaluation; | 2012 |
Recurrent seizures in a levetiracetam-treated patient after subarachnoid hemorrhage: a matter of enhanced renal function?
Topics: Anticonvulsants; Female; Humans; Levetiracetam; Middle Aged; Piracetam; Recurrence; Seizures; Subara | 2012 |
Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage.
Topics: Animals; Disease Models, Animal; Drug Administration Schedule; Head Injuries, Closed; Injections, In | 2006 |